Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company’s Board of Directors, effective July 16, 2019.
July 17, 2019
· 5 min read